icometrix Raises Over € 2M to Boost the Use of MSmetrix
News Jan 14, 2016
icometrix develops and markets MSmetrix, which is SaaS software to support radiologists and neurologists in the follow-up of Multiple Sclerosis patients. The company raised over €2 million additional capital. Investors include Capricorn ICT Arkiv, Annie Vereecken (Biover II), former Cartagenia (now part of Agilent Technologies) CEO Herman Verrelst, and current shareholders, such as the Universities of Antwerp and Leuven and the Antwerp University Hospital.
The proceeds will be invested to reach icometrix’ ambitious targets for 2016: increasing the use of MSmetrix worldwide, capacitating its branch office in the US, addressing new disease domains, and expanding their business in clinical trials and research studies. Other plans for 2016 include growing the icometrix sales force and development team and moving into a new office.
“By providing clinicians with standardized measurements on their patients’ brain MRI scans, icometrix improves personalized care of patients with a neurological disorder. Since its launch in March 2015 our product, MSmetrix, has helped more than 2000 patients in over 200 centers and 45 countries,” says Dirk Loeckx, CEO.
MSmetrix was developed for Multiple Sclerosis (MS) patients. It provides access to reliable measurements on the two main manifestations of MS in the brain, of which small but very significant changes are very difficult to see to the naked eye. Numbers on changes of lesion load and of brain volume over time are represented in an easy online report.
The reproducibility of the method is 0.1%, which is lower than the expected brain volume changes for MS patients. The automated measurements by icometrix provide a new piece to the puzzle of personalized patient treatment, complementary to the clinical investigation and radiological report.
Katrin Geyskens, Partner at Capricorn Venture Partners, sees a bright future for icometrix: “Digital healthcare is one of the fastest growing markets worldwide. It promises to increase the quality of life and reduce the cost of healthcare. icometrix has shown they can tailor their products to the needs of patients and doctors, in close collaboration with the different actors in the field. There is a lot of growth potential for icometrix, and their team has the capabilities to live up to it.”
Chinese researchers have developed interfacially polymerized porous polymer particles for low- abundance glycopeptide separation. These polymer particles - with hydrophilic-hydrophobic heterostructured nanopores - can separate low-abundance glycopeptides from complex biological samples with high-abundance background molecules efficiently.